Possible roles of Eucomis autumnalis in bone and cartilage regeneration: A review

In response to the recent alarming prevalence of cancer, osteoarthritis and other inflammatory disorders, the study of anti-inflammatory and anticancer crude medicinal plant extracts has gained considerable attention. Eucomis autumnalis is a native flora of South Africa with medicinal value. It has been found to have anti-inflammatory, anti-bacterial, anti-tumor/cancer, anti-oxidative and antihistaminic characteristics and produces bulb that have therapeutic value in South African traditional medicine. Despite the widely acclaimed therapeutic values of Eucomis autumnalis, its proper identification and proper knowledge, morphogenetic factors are yet to be efficiently evaluated. Similar to other plants with the same characteristics, E. autumnalis extract may stimulate bone formation and cartilage regeneration by virtue of its anti-inflammatory properties. This review provides data presented in the literature and tries to evaluate the three subspecies of E. autumnalis, highlighting their geographical location in South African provinces, their toxicity effects, as well as their phytochemistry and anti-inflammatory properties. Biologically active components, pharmacological importance and some environmental factors that can affect E. autumnalis are presented. The review also discussed the novel potential roles of E. autumnalis in regenerative medicine. Proper knowledge of the E. autumnalis plant and its possible role in bone and cartilage regeneration will help in addressing and clarifying its use in the production of drugs and for other therapeutic purposes, especially in the treatment of inflammatory diseases and cancer.Keywords: Medicinal plants, inflammatory diseases, toxicity, phytochemicals, bone regeneratio

Protecting participants in health research: The South African Material Transfer Agreement

The need to transfer human biological materials (HBMs) across national boundaries has become increasingly important in view of increased biobank and commercial activities globally. In light of South Africa (SA)’s history of colonisation and racial discrimination, coupled with well-known instances of exploitation of research participants in the developing world, it is critical that the management of HBMs from and to other jurisdictions is explored and regulated. Material transfer agreements (MTAs) represent an important point of departure in such a process. This article explores the need for a uniform MTA in SA and discusses some aspects of the recently gazetted national MTA, which provides a framework that can serve as a safeguard for cross-border transfer of HBMs in the absence of the National Health Act’s chapter 8 regulations in this regard

Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and In Vivo Efficacy in the Plasmodium falciparum NSG Mouse Model

A series of 2,4-disubstituted imidazopyridines, originating from a SoftFocus Kinase library, was identified from a high throughput phenotypic screen against the human malaria parasite Plasmodium falciparum. Hit compounds showed moderate asexual blood stage activity. During lead optimization, several issues were flagged such as cross-resistance against the multidrug-resistant K1 strain, in vitro cytotoxicity, and cardiotoxicity and were addressed through structure–activity and structure–property relationship studies. Pharmacokinetic properties were assessed in mice for compounds showing desirable in vitro activity, a selectivity window over cytotoxicity, and microsomal metabolic stability. Frontrunner compound 37 showed good exposure in mice combined with good in vitro activity against the malaria parasite, which translated into in vivo efficacy in the P. falciparum NOD-scid IL-2Rγnull (NSG) mouse model. Preliminary mechanistic studies suggest inhibition of hemozoin formation as a contributing mode of action

Identification of 2,4-disubstituted imidazopyridines as hemozoin formation inhibitors with fast-killing kinetics and in vivo efficacy in the Plasmodium falciparum NSG mouse model

A series of 2,4-disubstituted imidazopyridines, originating from a SoftFocus Kinase library, was identified from a high throughput phenotypic screen against the human malaria parasite Plasmodium falciparum. Hit compounds showed moderate asexual blood stage activity. During lead optimization, several issues were flagged such as cross-resistance against the multidrug-resistant K1 strain, in vitro cytotoxicity, and cardiotoxicity and were addressed through structure-activity and structure-property relationship studies. Pharmacokinetic properties were assessed in mice for compounds showing desirable in vitro activity, a selectivity window over cytotoxicity, and microsomal metabolic stability. Frontrunner compound 37 showed good exposure in mice combined with good in vitro activity against the malaria parasite, which translated into in vivo efficacy in the P. falciparum NOD-scid IL-2Rgamma(null) (NSG) mouse model. Preliminary mechanistic studies suggest inhibition of hemozoin formation as a contributing mode of action